Literature DB >> 27797615

Catching a Disease: A Molecular Trap as a Therapy for Pulmonary Arterial Hypertension.

Beth L Roman1, Cynthia St Hilaire1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27797615      PMCID： PMC5114453          DOI： 10.1164/rccm.201605-0920ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  21 in total

Review 1.  Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

Authors:  Alison M MacKenzie; Andrew J Peacock
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

2.  Endothelial-to-mesenchymal transition drives atherosclerosis progression.

Authors:  Pei-Yu Chen; Lingfeng Qin; Nicolas Baeyens; Guangxin Li; Titilayo Afolabi; Madhusudhan Budatha; George Tellides; Martin A Schwartz; Michael Simons
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

3.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  Induction of heart valve lesions by small-molecule ALK5 inhibitors.

Authors:  Mark J Anderton; Howard R Mellor; Alex Bell; Claire Sadler; Martin Pass; Steve Powell; Samantha J Steele; Ruth R A Roberts; Annabelle Heier
Journal:  Toxicol Pathol       Date:  2011-08-22       Impact factor: 1.902

5.  KLF4 mediates the link between TGF-β1-induced gene transcription and H3 acetylation in vascular smooth muscle cells.

Authors:  Ming He; Bin Zheng; Yu Zhang; Xin-Hua Zhang; Chang Wang; Zhan Yang; Yan Sun; Xiao-Li Wu; Jin-Kun Wen
Journal:  FASEB J       Date:  2015-06-16       Impact factor: 5.191

6.  Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).

Authors:  Roberto José Fajardo; Rajaram K Manoharan; R Scott Pearsall; Monique V Davies; Tod Marvell; Travis E Monnell; Jeffrey A Ucran; Amelia E Pearsall; Deepali Khanzode; Ravindra Kumar; Kathryn W Underwood; Benjamin Roberts; Jasbir Seehra; Mary L Bouxsein
Journal:  Bone       Date:  2009-09-23       Impact factor: 4.398

7.  Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

Authors:  Vicky Makker; Virginia L Filiaci; Lee-May Chen; Christopher J Darus; James E Kendrick; Gregory Sutton; Katherine Moxley; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2015-04-16       Impact factor: 5.482

8.  Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Yon K Sung; Deepti Sudheendra; Matthew Bill; Micheala A Aldred; Mariëlle C van de Veerdonk; Anton Vonk Noordegraaf; Janel Long-Boyle; Rajesh Dash; Phillip C Yang; Allan Lawrie; Andrew J Swift; Marlene Rabinovitch; Roham T Zamanian
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 9.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

10.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.

Authors:  Lu Long; Mark L Ormiston; Xudong Yang; Mark Southwood; Stefan Gräf; Rajiv D Machado; Matthias Mueller; Bernd Kinzel; Lai Ming Yung; Janine M Wilkinson; Stephen D Moore; Kylie M Drake; Micheala A Aldred; Paul B Yu; Paul D Upton; Nicholas W Morrell
Journal:  Nat Med       Date:  2015-06-15       Impact factor: 53.440
View more
  1 in total

1.  Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application.

Authors:  Taslim A Al-Hilal; Ali Keshavarz; Hossam Kadry; Behnaz Lahooti; Ahmed Al-Obaida; Zhenya Ding; Wei Li; Roger Kamm; Ivan F McMurtry; Tim Lahm; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Lab Chip       Date:  2020-08-04       Impact factor: 6.799
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.